May 27, 2025
Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap
Author(s): Emily Kaiser Maharjan Key Takeaways Aldeyra’s phase 3 trial of reproxalap showed statistical superiority in reducing ocular discomfort compared to the vehicle, supporting NDA resubmission. The unique chamber trial…